title: CD34 affinity pheresis attenuates a surge among circulating progenitor cells following vascular injury.
abstract: BACKGROUND
  Intimal hyperplasia (restenosis) is an exaggerated healing response leading to failure of half of vascular interventions. Increasing evidence suggests that circulating progenitor cells contribute to intimal pathology, and clinical studies have demonstrated a correlation between progenitor cells and the incidence of restenosis after cardiovascular interventions. The aims of this study were to characterize the temporal response of CD34+ progenitors following vascular injury in an ovine model and to evaluate an affinity pheresis approach to attenuate this response.
  
  
  METHODS
  An ovine model underwent either operative vascular injury or a nonvascular surgery (n = 3 per group). Blood was examined perioperatively over 2 weeks by flow cytometry. Next, an affinity pheresis approach to mediate systemic depletion of CD34 progenitors was designed. Custom agarose pheresis matrix with antibody affinity toward CD34 or an isotype control was evaluated in vitro. Next, following vascular injury, sheep underwent perioperative whole blood volume pheresis toward either the progenitor cell marker CD34 (n = 3) or an isotype control (n = 4) for 14 days. Animals were monitored by physical exam as well as complete blood counts. Cells recovered by pheresis were eluted and examined by flow cytometry.
  
  
  RESULTS
  Flow cytometry revealed a focal surge of circulating CD34 cells after vascular injury but not among surgical controls (P = .05). Toward the goal of an approach to attenuate the surge of CD34 progenitors, an evaluation of high-flow affinity matrix revealed efficacy in removal of progenitors from ovine blood in vitro. Next, a separate group of animals undergoing affinity pheresis after vascular injury was evaluated to mediate systemic depletion of CD34+ cells. Again, a surge of CD34+ cells was observed among isotype pheresis animals following vascular intervention but was attenuated over 20-fold by a CD34 pheresis approach (P = .029). Furthermore, an average of 77 million CD34-positive cells were eluted from the CD34 pheresis matrix. Despite multiple sessions of pheresis, complete blood counts remained essentially unchanged over 2 weeks.
  
  
  CONCLUSIONS
  Despite evidence suggesting a role for CD34+ circulating progenitor cells in restenotic pathology, the temporal pattern of CD34 progenitors after vascular injury has not been previously defined. We have demonstrated a surge among circulating CD34+ cells that appears confined to procedures involving vascular injury and that this event seems to occur early after vascular injury. We further conclude that CD34 affinity pheresis attenuates the surge. This approach for direct depletion of progenitors may have important implications for the study of progenitors in vascular restenosis.
authors.affiliation: Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pa.
authors.forename: Adriana
authors.initials: A
authors.lastname: Harbuzariu
authors.affiliation: Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pa.
authors.forename: Justine
authors.initials: J
authors.lastname: Kim
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa.
authors.forename: E Michael
authors.initials: EM
authors.lastname: Meyer
authors.affiliation: McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pa; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa; University of Pittsburgh Cancer Institute, Pittsburgh, Pa.
authors.forename: Albert D
authors.initials: AD
authors.lastname: Donnenberg
authors.affiliation: Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pa. Electronic address: tillmanbw@upmc.edu.
authors.forename: Bryan W
authors.initials: BW
authors.lastname: Tillman
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000276:immunology*; D001781:Blood Component Removal / Q000379:methods*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000276:immunology* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D012756:Sheep; D013234:Stem Cells / Q000166:cytology / Q000276:immunology*; D016896:Treatment Outcome; D057772:Vascular System Injuries / Q000473:pathology / Q000628:therapy*
chemical_list: D018952:Antigens, CD34